Global Healthcare Information Systems Market By Major Industry Trends And Forecast Business Opportunities And Threats In The Next 5 Years

 The global healthcare information systems market is expected to register a CAGR of 10.0% during the forecast period of 2018 to 2023.

Healthcare information technology offers solutions for security and data management of information related with healthcare. Currently, information technology has more effect on the cost quality and safety associated with healthcare. Some commonly used applications in the healthcare industry include electronic medical records, healthcare records and personal health records.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7325

Healthcare Information Systems Market Segmentation

The global healthcare information systems market is segmented based on type, components, deployment, end user, and region.

On the basis of type, the market is segmented into hospital information systems, pharmacy information systems, laboratory information systems, medical imaging information system, revenue cycle management. The hospital information systems segment is sub-segmented into electronic health record, electronic medical record, real-time healthcare, patient engagement solutions, population health management and others. The pharmacy information systems segment is sub-segmented into prescription management, automated dispensing systems, inventory management and others. The medical imaging information System is sub-segmented into radiology information systems, monitoring analysis software, picture archiving & communication systems and others. Based on components, the market is divided into two, i.e., Software and Hardware. Based on deployment, the market is divided into web-based, on premise and cloud-based. By end user, the market is divided into hospitals, diagnostics centre, academic and research institution, and others. In the current scope of the study, the above-mentioned segments are covered into four global regions, namely- the Americas, Europe, Asia Pacific and the Middle East & Africa.

Healthcare Information Systems Regional Market Summary

The Americas dominated the global market of healthcare information systems. Rising demand for high quality diagnostics system is the main reason behind the supremacy of the North America’s healthcare information system market. Furthermore, large-scale implementation and storage of electronic records in the healthcare system witnessed in the countries such as Canada and the U.S is supporting the expansion of this regional healthcare information system market.

In 2017, it was estimated that Europe stood second in the global healthcare information systems market. This can be attributed due to the presence of a well-developed healthcare infrastructure, increasing awareness for the condition and presence of developed economies within the region.

Asia Pacific was the fastest growing region for the global healthcare information systems market in 2017. Asia-Pacific has a huge market potential for Healthcare IT industry. India and China are some of the rapidly growing countries, followed by South Korea. Consequently, the government in these rapidly developing economies have taken various efforts to improve healthcare services and provide better infrastructure.

On the other hand, the Middle East and Africa held least share in the global healthcare information systems market. Presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. Most of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-information-systems-market-7325

Radiofrequency Ablation Devices Market To Show Steady Growth, 2023

 The global radiofrequency ablation devices market is expected to register a CAGR of 11.2% during the forecast period of 2018 to 2023.

Radiofrequency ablation (RFA) uses thermal energy to achieve targeted tissue destruction. Within the GI tract, Radiofrequency ablation was primarily studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be one of the common applications. Indications for Radiofrequency ablation within the GI tract continue to progress. It has been used in the treatment of esophageal squamous cell dysplasia, cholangiocarcinoma, radiation proctopathy, gastric antral vascular ectasia (GAVE), and pancreatic neoplasia, among other conditions.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7634

Radiofrequency ablation devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the radiofrequency ablation device in the radiofrequency range of 450 to 500 kHz.

Segmentation

The global radiofrequency ablation devices market is segmented on the basis of type, application, and region.

On the basis of the type, the global radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation. By application, the global radiofrequency ablation devices  market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain Management

Key players

Some of the key players in the global radiofrequency ablation devices  market are Boston scientific corporation, Medtronic Inc, Stryker, Cosman Medical, Inc., St. Jude Medical, Smith & Nephew, Johnson & Johnson (J&J) Services, LLC, Angiodynamics, RF Medical Co, Ltd, AtriCure, Inc., and others

Regional Market 

The Americas dominates the global market for radiofrequency ablation devices owing a growing number of lung cancer cases like, Non-Small Cell Lung Cancer (NSCLC) which is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases. It is generally a slow growing and spreading as compared to small cell lung cancer (SCLC). Small cell lung cancer used to account for 12-13% of lung cancers. However, there has been a shift from NSCLC to SCLC in recent years which has propelled the growth of the radiofrequency ablation devices market.

In 2017, it was estimated that Europe stood second in the global radiofrequency ablation devices market.

Asia-Pacific was the fastest growing region for the global radiofrequency ablation devices market in 2017. Factors such as increasing awareness of the cardiac disease, growing healthcare industries, and the development of various treatment methods for gynecology and cosmetology drives the market in this region.

On the other hand, the Middle East and Africa holds the least share in the global radiofrequency ablation devices market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/radiofrequency-ablation-devices-market-7634

Q fever Market Segmentation Detailed Study With Forecast Up To 2023

 The Global Q fever market is expected to grow at CAGR of 7.83% to reach USD 6,249.68 thousand till 2023. Some of the protuberant drivers supporting the growth of the global Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.

The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the global Q fever market in coming years.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5490

Segmentation

Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand by the end of 2023. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.

Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.

The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.

On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1% as of 2017.

 

Regional Analysis

The Asia-Pacific accounted for the largest market share of 44.5% as of 2017 and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.  

The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.

The Americas accounted for a significant share in the global Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.

Key Players

The prominent players in the global Q fever market are Merck KGaA (Germany), Teva Pharmaceutical (Israel), Pfizer Inc. (US), Basilea Pharmaceutica Ltd (Switzerland), Sanofi S.A.(France), Melinta Therapeutics, Inc. (US), Bayer AG (Germany), Johnson & Johnson Services, Inc. (US), Yashica Pharmaceuticals (India), AtoxBio (US), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/q-fever-market-5490

Hemostasis and Tissue Sealing Agents Market To Observe Significant Growth By 2023

 

Hemostasis and Tissue Sealing Agents Market Scenario

Global hemostasis and tissue sealing agents market is expected to grow significantly and is projected to grow at a CAGR of 8.6% over the forecast period. Hemostats, adhesives and sealants are useful aides to modern surgical procedures. Topical hemostats are utilized intraoperatively first and postoperatively to a reduce extent. These products can be utilized to diffuse raw surface bleeding, bone bleeding, oozing venous type bleeds, and needle-opening bleeding. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Surgical procedures are medical interventions involving an incision with instruments usually performed in an operating theatre and normally involving various medical devices such as catheters and tubes. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S. Additionally, according to the NHS, surgery is the most important treatment offered by the NHS in secondary care within the UK. Furthermore, in 2015, NHS estimated that there were around 4.7 million surgical admissions in England, out of which 1.3 million procedures were for general surgery and around 1.2 million procedures were for trauma and orthopedics.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7559

These high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market.    

Hemostasis and Tissue Sealing Agents Market Segmentation

 

The global hemostasis and tissue sealing agents market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

The global Hemostasis and tissue sealing agents market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diagnostics imaging workstations market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European Hemostasis and tissue sealing agents market has been segmented into Western Europe and Eastern Europe. The Western Europe diagnostics imaging workstations market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The diagnostics imaging workstations market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diagnostics imaging services market in the Middle East & Africa has been segmented into the Middle East and Africa.

Hemostasis and Tissue Sealing Agents Market Key players

 

Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc

Hemostasis and Tissue Sealing Agents Regional Market Summary

Geographically, the Americas is anticipated to dominate the global hemostasis and tissue sealing agents market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The Hemostasis and tissue sealing agents market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hemostasis-tissue-sealing-agents-market-7559

Transdermal (Percutaneous) Drug Delivery Systems Market Expected To Boost During 2020 To 2023

 The global transdermal (percutaneous) drug delivery systems market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 5,400.2 million in 2017 and is projected to grow at a CAGR of 4.6% during the forecast period from 2018 to 2023. Transdermal drug delivery system (TDDS) delivers drugs through the skin to systemic circulation at a predetermined rate and maintain the effective concentrations clinically over an extended period. TDDS also called as patches are dosage forms that deliver a therapeutically effective amount of drug via the patients’ skin. Worldwide growing geriatric population along with rising in the prevalence of chronic diseases is the leading factor driving the market growth. In addition, rapid technological advancements in transdermal drug delivery systems and increasing adoption of third-generation delivery systems are expected to augment the market growth during the forecast period. The geriatric population is more prone to develop Q fever. The elderly population across the world is on the surge. The World Health Organization (WHO) reported that the worldwide population aged 60 years and above was 962.0 million in 2017, which is projected to increase to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7545

However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin’s impermeability, and lack of adhesion of the transdermal system to different skin types are anticipated to hinder the market growth over the forecast period. Additionally, drugs that require high blood levels cannot be administered through TDDS as it is limited only to potent molecules, those requiring a daily dose of 10 mg or less, thereby affecting the market growth.

Transdermal Drug Delivery Systems Market Segmentation

 

The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.

By product, the market has been segmented into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches. The transdermal semisolids segment is additionally divided into gels, ointments, and sprays. The transdermal patches segment spearheaded the market in 2017 due to its benefits offered such as improved bioavailability, reduced dosing frequency, lower adverse events, enhanced patient compliance (non-invasive nature), painless application, and drug input termination at any point by the removal of the patch.

On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.

Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.

The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transdermal (percutaneous) drug delivery systems market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European transdermal (percutaneous) drug delivery systems market has been segmented into Western Europe and Eastern Europe. The Western Europe transdermal (percutaneous) drug delivery systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The transdermal (percutaneous) drug delivery systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545

Global Vitamin K2 Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2020-2023

 The global vitamin K2 market is estimated to touch a valuation of USD 228.27 million by 2023, as per the latest findings of Market Research Future (MRFR). It is predicted to register 31.08%% CAGR over the forecast period (2018-2025). It was previously valued at USD 45 million in 2017. It is primarily driven by the rise in vitamin deficiency cases. An increase in health consciousness coupled with the inclination of consumers towards nutritional supplements can drive the vitamin K2 market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7495

Rising cases of osteoporosis which can accelerate the aging of tissues is another factor that can positively impact the market. But strict regulations by government federal agencies for approval of supplements can act as a growth deterrent.

Competitive Landscape

Key players in the global vitamin K2 market report include Kappa Bioscience (Norway), NattoPharma (Norway), Gnosis SpA (Italy), Viridis BioPharma (India), Seebio Biotech (China), DSM (The Netherlands), Danisco A/S (U.S.), Geneferm Biotechnology Co. Ltd. (Taiwan), Frutarom (Israel), and Kyowa Hakko Bio Co. Ltd. (Japan).

Segmentation Overview

The global vitamin K2 market is segmented on the basis of product type, source, form, and application.
By product type, the market is segmented into MK-4, MK-7, and others. ‘Others’ include MK-5, MK-8, MK-9, and MK-10. Two major sources discussed include natural and synthetic.
By form, the market is bifurcated into oil and powder. Major applications include nutraceutical & food and pharmaceutical.
For the scope of the report, the global vitamin K2 market is segmented in the following manner

Product Type

• MK-7
• MK-4
• Others

Source

• Natural
• Synthetic

Form

• Oil
• Powder
• Others

Application

• Nutraceutical & Food
• Pharmaceutical

Regional Overview

Based on regions, the global vitamin K2 market is segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas held a major market share in 2017 owing to rocketing healthcare costs, focus on health and wellness by consumers, and adoption of herbal medicines. On the other hand, the European region can register a stupendous growth rate thanks to demand for vitamin supplements in Germany, France, and the U.K

Research Methodology

At Market Research Future, we consider the proper blend of accurate, reliable, and relevant data as of prime importance. Our data analysts are adept in exactly interpreting data and gaining appropriate information. The primary research includes a head-to-head interview with eminent market insiders who have a pulse on market trends. The secondary method amplifies pertinent factors of the market that can positively influence the market during the forecast period. Other credible sources such as annual reports, publications by relevant associations, and SEC filings do play an integral part in the planning of the report. To maintain an objective analysis, we have included several proprietary standards for the estimation and validation of market data. Top-down and bottom-up approaches are a part of this analysis for a holistic understanding of the market, and the endeavor is to provide our clients with an edge that would help them gain insights.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/vitamin-k2-market-7495

Worldwide Organic and Natural Feminine Care Market 2020 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2023

 Organic and natural feminine hygiene products, also known as menstrual products, are derived from organic cotton. The biodegradable nature of these products makes it appealing to women who use it to treat sensitive skin and tissues in the vaginal area.

The global and North America organic and natural feminine care market is poised to reach a value of USD 3,990.93 million by 2023, as per the latest findings of Market Research Future (MRFR). The inclination of women towards organically derived products is likely to propel the market to exhibit 7.06% CAGR over the forecast period (2018-2023). Organic products can reduce the probability of acquiring cancer and other chronic diseases.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7441

Initiatives by nations to create awareness and negate the taboo of menstruation is likely to induce massive demand for organic and natural feminine care products. In May 2018, the government of India launched an affordable pad under a special scheme to make it available for women in rural areas. But shortage of organic and natural feminine care products in supermarkets can act as a growth deterrent in the market.

Segmentation Overview

The global and North America organic and natural feminine care market is segmented on the basis of product and distribution channel. Products include sanitary pads, panty liners & shields, and tampons. Major distribution channels considered for the sale of these products include supermarkets & hypermarkets, retail pharmacies, and online purchase.

Regional Overview

Based on regions, the global and North America organic and natural feminine care market is segmented into North America, South America, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). North America is projected to lead the market till 2023 thanks to high awareness of feminine care among women. In addition, easy availability at retail and online channels can also be a factor fueling the market growth. APAC is expected to exhibit a robust CAGR over the forecast period owing to high scope for organic feminine care products in India, China, and South Korea. The high retention capacity of these products is primarily driving the demand in the region.

Competitive Landscape

Prominent players in the global and North America organic and natural feminine care market report include Procter & Gamble (U.S.), Armada & Lady Anion (Australia), Bodywise Limited (U.K.), Corman USA Inc. (U.S.), GladRags (U.S.), Heyday Care LLP (India), Maxim Hygiene (U.S.), Apropos (U.S.), Purganics (India), Rael (U.S.), Saathi (India), The Honest Company Inc. (U.S.), Tosama (Slovenia), and Veeda USA (U.S.).

The market is characterized by novel product launches and collaborations. This is exemplified by the rebranding of the Organyc line of products by Corman in 2017. It collaborated with reputed e-tailers such as CVS Pharmacy and Amazon in order to make its products available to a large audience simultaneously.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/organic-natural-feminine-care-market-7441